Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TLXBullishCorporate Developmentsnews

High materiality8/10

Telix reports BiPASS enrollment complete; FDA NDA pathway could broaden PSMA-PET access

Sep 1, 2026, 6:21 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory progress and enrollment milestones often trigger near-term stock moves, especially for a commercial-stage radiopharma with established imaging products and a large addressable market. If the NDA pathway progresses toward reimbursement approvals, TLX could re-rate on expanded access and potential payer coverage.

AI summary

What happened, with direct paths to the underlying reporting

Telix announced BiPASS Phase 3 enrollment is complete at 350 patients and disclosed progress toward an FDA NDA pathway to support reimbursement and broaden access to 68Ga-PSMA-PET imaging with MRI before biopsy. If successful, BiPASS could expand PSMA-PET beyond staging, reduce unnecessary biopsies by roughly 50% per prior studies, and widen patient access to Telix’s imaging agents.

BiPASS Phase 3 enrollment reached 350 patients. Telix engages FDA NDA pathway.
BiPASS studies 68Ga-PSMA-PET with MRI pre-biopsy. Could shift diagnosis.
Global three million annual prostate biopsies; up to 75% negative. Potential health-cost relief.
Enrollment completed in U.S. and Australia; BiPASS is first registrational pre-biopsy PSMA-PET.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.